Tominersen is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Huntington Disease. According to GlobalData, Phase III drugs for Huntington Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Tominersen LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tominersen (RG-6042) is under development for the treatment of Huntington's disease. The drug candidate is administered through intrathecal route. It is a chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA. It is based on antisense technology and brain shuttle technology. It is a new molecular entity (NME) and acts by targeting HTT.
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
For a complete picture of Tominersen’s drug-specific PTSR and LoA scores, buy the report here.